CapsoVision shares rise 22.20% intraday after amending Canon development agreement to boost CMOS sensor specs for FDA 510k approval.

CapsoVision surged 22.20% intraday, driven by a modified $1 million development agreement with Canon to enhance CMOS image sensor specifications, increasing total development costs to over $5.1 million. This supports clinical evaluation and FDA 510k approval for its capsule endoscopy system, which features improved sensor performance. As a commercial-stage medical technology company, CapsoVision specializes in gastrointestinal diagnostic imaging, with its flagship CapsoCam Plus offering 360-degree panoramic view technology for wireless small intestine capsule endoscopy solutions.